Meeting Report

“Development of Fixed Dose Combination Products” Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy

Bart Hens,1,11 Maura Corsetti,2,3 Marival Bermejo,4 Raimar Löbenberg,5 Pablo M. González,6 Amitava Mitra,7 Divyakant Desai,8 Dakshina Murthy Chilukuri,9 and Alexis Aceituno10

Abstract. The gastrointestinal (GI) tract is one of the most popular and used routes of drug product administration due to the convenience for better patient compliance and reduced costs to the patient compared to other routes. However, its complex nature poses a great challenge for formulation scientists when developing more complex dosage forms such as those combining two or more drugs. Fixed dose combination (FDC) products are two or more single active ingredients combined in a single dosage form. This formulation strategy represents a novel formulation which is as safe and effective compared to every monoprod separately. A complex drug product, to be dosed through a complex route, requires judicious considerations for formulation development. Additionally, it represents a challenge from a regulatory perspective at the time of demonstrating bioequivalence (BE) for generic versions of such drug products. This report gives the reader a summary of a 2-day short course that took place on the third and fourth of November at the Annual Association of Pharmaceutical Scientists (AAPS) meeting in 2018 at Washington, D.C. This manuscript will offer a comprehensive view of the most influential aspects of the GI physiology on the absorption of drugs and current techniques to help understand the fate of orally ingested drug products in the complex environment represented by the GI tract. Through case studies

1 Department of Pharmaceutical & Pharmacological Sciences, KU Leuven, Herestraat 49, Gasthuisberg, Box 921, 3000, Leuven, Belgium.
2 NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
3 Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.
4 Department Engineering Pharmacy Section, Miguel Hernandez University, San Juan de Alicante, 03550, Alicante, Spain.
5 Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H7, Canada.
6 Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av Vicuña Mackenna, 4860, Santiago, Chile.
7 Clinical Development, Sandoz, Inc. (A Novartis Division), Princeton, New Jersey 08540, USA.
8 Drug Product Science and Technology, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903-0191, USA.
9 Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA Silver Spring, US Food & Drug Administration (US FDA), Prince Georges Counties, Maryland, USA.
10 Subdepto. Biofarmacia y Equivalencia Terapéutica, Agencia Nacional de Medicamentos (ANAMED), Instituto de Salud Pública de Chile, Santiago, Chile y Facultad de Farmacia, Universidad de Valparaíso, Valparaíso, Chile.
11 To whom correspondence should be addressed. (e-mail: bart.hens@kuleuven.be)
on FDC product development and regulatory issues, this manuscript will provide a great opportunity for readers to explore avenues for successfully developing FDC products and their generic versions.

**KEY WORDS:** bioequivalence; fixed dose combination drug products; formulation prediction; in vivo predictions; gastrointestinal physiology.

**FROM STOMACH TO LARGE INTESTINE: A THOROUGH REVIEW OF GASTROINTESTINAL PHYSIOLOGY—MAURA CORSETTI M.D., PH.D. AND BART HENS PHARM.D., PH.D.**

From an anatomical point of view, the stomach is divided into a fundus, corpus (i.e., body), and antrum region, but when it comes to motor function, two parts can be distinguished: the proximal stomach, consisting of the fundus and the proximal part of the corpus and the distal stomach, consisting of the distal part of the corpus and the antrum. The motility of the proximal stomach is characterized by a maintained status of contractions of the smooth muscle (tone), whereas the distal stomach generates phasic contractions. During the inter-digestive phase, the proximal stomach muscle tone is high, whereas the distal stomach is engaged in a recurrent motor pattern known as the migrating motor complex (MMC) (1,2). This complex involves the stomach and the majority of the small bowel (but not the distal small bowel) with three phases: phase I, a quiescent phase with no contractions; phase II with until recently considered random contractions; phase III with a sudden onset of repetitive contractions that also ends abruptly. The phase III can start in the stomach or in the proximal small intestine and then migrate towards the distal ileum. Gastric pH fluctuates during the MMC, with the antral pH being lowest (more acidic) just prior to the start of phase III contractions and higher at the start of phase I. This change in pH is due to an increase in acid and pepsin secretion that accompanies phase III of the MMC, and bile-free, bicarbonate reflux from the duodenum (3,4). Intestinal and pancreatic secretions (e.g., water, bicarbonate, and pancreatic enzymes) increase during phase III contractions of the small intestine (2,4). As soon as the food is ingested, the proximal stomach will relax to accommodate the food, followed by a tonic contraction of the proximal stomach which will push the food more distally. The distal stomach will mix and grind the food by powerful and regular contractions (5,6). The duodenum is exposed to nutrients almost directly after the ingestion of food and this will activate a multitude of duodenogastric negative-feedback mechanisms, as for instance mediated through vagal reflexes and hormonal signals. This will delay the arrival of acidic, hyperosmotic, or caloric-rich gastric contents into the duodenum by inhibiting proximal gastric tone, and phasic contractions, stimulating the closure of the pylorus (7). The physical consistency, fat content, and caloric load of the meal play a relevant role in regulating the motor response of the stomach. Liquids of low caloric density empty under the pressure gradient created by the fundus tone and the little motor action of the distal stomach in an exponential fashion. Digestible food of more solid consistency requires antral trituration until the particle size is reduced (8). The time that the stomach takes to reduce the particles may explain the lag phase observed before emptying can start. Thus, gastric emptying occurs in two periods: the lag period (responsible for digestion of solid material) and the post-lag, a linear emptying period when digested solid particles or liquids can easily be emptied from the stomach. Non-digestible solids are usually emptied from the stomach with the inter-digestive phase III of MMC (8). A recent study demonstrated the impact of these phase III contractions to clear ibuprofen from the stomach into the small intestine (9). These contractions in combination with the pH played a pivotal role in the onset of intestinal absorption, determining the plasma $C_{\text{max}}$ and $T_{\text{max}}$. A clinical aspiration study was recently performed to investigate the gastric emptying rate of a glass of water in fasted and fed state conditions (10). A standardized dose of phenol red was added to the glass of water and ingested by healthy subjects. After drinking the glass of water, gastrointestinal (GI) fluids were aspirated from the stomach, duodenum, and jejunum. Based on computational modeling, authors identified that gastric emptying of a glass of water is tremendously rapid, especially in a fasted state, and will be triggered by the present motility at the time of water administration (10–12). Scintigraphy is considered the gold standard to study gastric emptying in humans, and this is normally defined by the percentage of gastric retention at 1 h, 2 h, and at 4 h. However, the use of a single summary outcome measurement does not allow capturing the above-reported complex mechanisms activated by a meal (13). Nottingham has validated and published the normal values of a gastric emptying test based on a liquid meal, as described by Parker and co-workers, to obtain a comprehensive assessment of gastric motor and sensory function (13,14). This test allows differentiating an early and a late phase of gastric emptying for a liquid meal that may reflect the gastric accommodation and the antral component of the gastric emptying (13,14). Recently, two techniques have been developed to study the gastric function. The SmartPill® is an ingestible device (26 mm by 13 mm) measures intraluminal pH, pressure, and temperature. It wirelessly transmits data to a wearable external recorder, allowing ambulatory studies at home (15,16). The variations in luminal pH, as well as the drop in temperature after defecation, allow accurate measurement of regional as well as whole gut transit times. However, it should be noted that in consideration of the dimension of the device does not reflect the gastric emptying of normal digestible food and indeed, the gastric emptying has been found to be longer than that measured by scintigraphy (16). In any case, this technique has the advantage of being non-invasive and of combining the measurement of pH and of the whole gut transit time. Besides telemetric capsules, magnetic resonance imaging (MRI) has been recently applied to the study the GI function and this technique offers some major advantages compared to other techniques: it is non-invasive, does not expose subjects to ionizing radiation, and does not require any contrast medium. It is a unique technique that offers the possibility of simultaneously measuring gastric, small intestinal, and...
colonic volumes; the physicochemical characteristics of the luminal environment; and transit rate, and quantifying motility (17). This technique has not yet been standardized across research centers and for the moment, it does not allow the evaluation of gastric function in an upright position (18). In summary, the human stomach is more complex as it seems and can play a major role in further intraluminal drug behavior along with the intestinal tract where absorption takes place.

Beyond the stomach, the intraluminal processes in the small intestine will play a pivotal role with respect to drug absorption. There is a specific focus on (i) the residual intestinal fluid volumes, (ii) the characterization and composition of the intestinal fluids, and (iii) the permeability of the intestinal wall for drug compounds. The residual fluid volumes in the intestinal tract are rather scarce and not homogenously distributed as a pool of water from the proximal towards the distal part. Distribution of these fluids is organized in different fluid pockets (12,19). The variability in the number of pockets and the actual volume for each pocket is tremendously high between healthy subjects, as highlighted by Mudie and co-workers (12). This finding was an important investigation for formulation scientists to be aware of the fact that the intestinal tract is not like a “swimming pool,” completely filled with water. The prediction of the in vivo performance of orally administered drug products has shown to be more accurate when applying the fluid dynamics as observed by Mudie et al. instead of using static and high volumes (12). This was observed for posaconazole, a weakly basic compound, for which the in vivo performance was predicted by using a dynamic fluid and pH model in simulation software (20). Although this model shows to have an impact on predicting the in vivo performance for compounds suffering from a poorly aqueous solubility, authors concluded that this model may not have an immense impact on the predicted systemic exposure for compounds characterized by a high solubility. Moreover, as mentioned before, there is huge intersubject variability in the number and volume of pockets. For instance, one subject showed to have only 2 pockets with a total volume of 1.4 mL, whereas another subject demonstrated to have 23 pockets with a total volume of 160 mL. A follow-up study aims to unravel a potential link between the appearance of fluid pockets and the present motility (17). In the 1970s, Vantrappen et al. observed a higher secretion rate of bicarbonate shortly after an upper GI phase III contraction (4). In doing so, the gastric acid of the stomach entering the small intestine could directly be neutralized by the bicarbonate buffer. This so-called secretomotor complex is highly likely to be a responsible factor in the formation of water pockets inside the intestinal tract. Besides gaining knowledge with respect to the present volumes in the GI tract, the composition of these fluids is another important aspect. In a recent study, human duodenal fluids were aspirated from 20 healthy subjects in the fasted and fed state (21). The fed state was simulated by ingestion of a liquid meal (i.e., 400 mL of Ensure Plus®, equal to 700 cal). After aspiration of these fluids as a function of time, fluids were analyzed for pH and endogenous constituents (bile salts, phospholipids, cholesterol, enzyme activity, and lipid digestion products). The results of this study demonstrated wide variability in the presence of these constituents from person to person, although the study protocol was the same for each and every individual (21). Especially for ionized compounds, the present pH in the intestinal tract is extremely important in order for a drug to dissolve and, subsequently, to be absorbed. The research group of Prof. Amidon (University of Michigan) aspirated GI fluids from 37 healthy subjects after oral intake of an immediate-release ibuprofen tablet (800 mg) in fasted and fed state conditions (9,22). Fluids were aspirated from different segments of the GI tract: stomach, duodenum, and jejunum. This study demonstrated the highly fluctuating pH, especially in the duodenum, which was an important intrinsic factor besides motility explaining differences in systemic exposure of ibuprofen between and within subjects (Fig. 1).

Besides solubility, absorption has always been a key parameter in the estimation of drug performance. Multiple techniques are described in the literature to assess the intestinal permeability of drug compounds. The Loc-I-Gut® method, i.e., a double-balloon perfusion system, is an interesting study technique to explore the permeability for drug compounds in the different regions of the GI tract (23,24). A specific region of the GI tract will be inflated by two balloons and thus separating a specific region of interest. Subsequently, a drug solution will be perfused and the amount of drug that will disappear is a measure for the amount of drug absorbed. The application of this technique has unraveled the intestinal permeability for hydrocortisone in the duodenum, jejunum, and ileum. A recent review by Dahlgren et al. compiles historical Papp data from 273 individual measurements of 80 substances from 61 studies performed in all parts of the human intestinal tract (25). This impressive data set has served as a reference for researchers in order to optimize the protocols of in vitro setups in order to improve the predictive performance of their in-house absorption tools (26).

With respect to the colonic physiology, recent findings, applying high-resolution manometry (HRM), have demonstrated that colonic motility is mainly represented by non-propagating and retrograde activity and both these activities increased soon after intake of a meal. These colonic motor patterns have the role of delaying the arrival of colonic content to the rectum and of favoring the retrograde filling of the transverse and ascending colon, where the propagating contractions normally start. Propagating contractions, including the high-amplitude propagating contractions associated with movements of solid colonic content, represent a minority of the colonic activity and are normally more frequent about 1–2 h after the meal and upon awakening (27). The reason of this is highly likely related to the fact that, in these moments of the day, the arrival of the content accumulated in the distal small bowel during the night and during the inter-digestive periods determine the distension of the ascending and transverse colon that trigger the propagating activity. The prevalence of non-propagating activity explains the fact that the normal colonic transit time is slower (about 35 h) as compared to the small bowel. This allows the colon to perform its functions of absorption and fermentation and to be an adequate reservoir organ. HRM is a useful technique to study colonic motor function but is invasive and normally requires preparation of the bowel. This makes the technique less attractive when the colonic function needs to be studied
under physiological conditions. Recently, other techniques have been applied to study the colonic function. The electromagnetic capsule is an ingestible silicone-coated cylindrical magnet (21 mm by 8 mm) is used to map the real-time movements of colonic contents. A plate containing a detection matrix of 4 × 4 magnetic field sensors is worn by an ambulatory patient around the abdomen to detect the movements of the pill. This matrix allows mapping of the pill movements in the x-, y-, and z-axis as well as the inclination angles applied by the colon. The pill allows evaluation of the direction (anterograde and retrograde), velocity, and length of movement of intraluminal content allowing the calculation of the colonic transit time. Recent studies have also demonstrated the first identification of colonic motor patterns consistent with those seen with HRM (28). Moreover, MRI has also been introduced as it is able to measure both the colon free water content and the fluidity of the colonic content (29). Recent animal studies have demonstrated that the colon is able to adapt to the physical characteristics of the intraluminal content and develops different motor response according to the presence of more or less fluid content (30). It is highly likely that these physiological variables play a pivotal role in the dissolution and/or absorption of drugs that are triggered to be released at the colonic site in the human GI tract.

INTEGRATION OF GI PHYSIOLOGY INTO A PREDICTIVE DISSOLUTION DEVICE: WHERE TO START?—RAIMAR LÖBENBERG PH.D.

The GI tract is a complex and not well-understood sequence of organs with changing environments as a function of time. However, an in-depth mechanistic understanding of the obstacles and opportunities in each segment is necessary to achieve optimal drug absorption and bioavailability (BA) (Fig. 2).

Figure 2 shows multiple factors impacting the fraction dose absorbed without considering metabolic or drug stability compromising degradation processes. The Biopharmaceutics Classification System (BCS), represented by the blue box, focuses on permeability and solubility (31). However, drug dissolution and solubility depend on additional physiological factors that are summarized in the red box. Motility effects and gastric emptying are known to have an impact on the performance of a drug product but they are seldom considered in drug development. In contrast, food effects, pH effects, and solubilization effects by bile salts were studied intensively in the past decades. However, today, there is still no consensus on a universal dissolution media, which can be used in drug development and for in vitro performance testing to capture these effects. Early studies evaluated the solubility of glyburide, a BCS class II drug, in biorelevant media (32). It was shown that the increased solubility in bile salt media (containing sodium taurocholate and egg lecithin) was suitable to establish an in vivo-in vitro correlation (IVIVC) when computer simulations were applied. Linear regression was established in GastroPlus™. Applying a biorelevant solubility value resulted in a regression coefficient of 0.94 for the reference formulation. The prediction error (%) regarding simulated plasma $C_{\text{max}}$ and AUC was 7 and 14%, respectively, when using these biorelevant solubility values as an input in GastroPlus™. Solubility values obtained in aqueous media (pH 6.5) resulted in a 38 and 63% prediction error with respect to plasma $C_{\text{max}}$ and AUC. Later on, a dynamic dissolution protocol was developed in biorelevant media (i.e., FaSSIF) which again showed predictive power for establishing an IVIVC (33). The dynamic dissolution protocol was then applied to a flow-through apparatus for montelukast sodium. Again, the biorelevant
media gave the best fit to clinically observed data (34). These early studies were successful to establish IVIVC without considering other GI factors. In a study by Almukainzi et al., the impact of gastric motility on the pharmacokinetics (PK) of meloxicam was studied (35). It was observed that two formulations (conventional versus fast dissolving) had a similar PK pattern when administered in a rodent model. However, when the gastric motility was impaired, the stomach controlled the drug release and therefore, the drug absorption for the conventional dosage form. The PK of the fast dissolving formulation was close to the pattern observed in the healthy state. This study indicated that formulation differences, which are not relevant under healthy conditions, might result in significant differences under disease state. This study showed that the stomach in disease conditions is able to negatively impact PK parameters such as plasma $C_{\text{max}}$ and $T_{\text{max}}$. Furthermore, it is well accepted that gastric emptying impacts the PK in fasted versus fed state for many drugs. However, less attention is given to the fact that GI motility impacts with $\text{MMC}$. This might be due to the fact that PK models used to quantify and describe the PK behavior of drugs sooth out individually observed variability in the mean PK profiles. However, if motility and PK are both monitored, a relationship between observed plasma levels and intestinal motility is getting more obvious. Another factor for alternations in drug absorption is the composition of the intestinal juices. The buffer system in the GI tract is carbonate-based. In routine pharmaceutical quality control (QC) and development, phosphate buffers play a major role while carbonate buffers are seldom used. The choice of phosphate over bicarbonate seems to impact the in vivo performance of enteric-coated dosage forms. Early reports show the failure of enteric-coated products in vivo (1964) and are confirmed over several decades until today by in vivo studies (36–38). Also, there is evidence that phosphate and carbonate buffers seem to interact differently with the enteric-coated polymers. It is obvious that a re-evaluation of established in vitro testing is important to capture in vivo relevant performances to avoid product failure. The next important differences, besides buffer nature, are buffer strengths used in in vitro dissolution protocols versus the present buffer strength in the GI tract and the impact of the intestinal absorption on drug dissolution. Biphasic dissolution is known for many years as a surrogate to assess the in vivo performance of a drug formulation (39). Based on the permeated amount of drug appearing in the organic layer, estimations related to the fraction absorbed can be performed (40). However, its impact on IVIVC has not yet been fully appreciated. In a recent study, we investigated the dissolution behavior of ibuprofen in pharmacopeial and GI equivalent phosphate buffer strength. The results showed that ibuprofen dissolved fully under the pharmacopeial conditions in less than 15 min. However, at low buffer strengths, this process took much longer, and the pH of the media changed significantly due to the acetic nature of ibuprofen. However, if a biphasic dissolution test was performed, the pH recovered over time close to the original value. This again demonstrates how important physiologically adapted in vitro testing can be to capture what happens in vivo. Only this can ensure that in vitro methods are predictive of in vivo performance. The translation of such methods into QC methods needs to be investigated in the future in more details. The last aspect deals with the irrelevance of in vitro behavior on the drug product performance in vivo. An example of such a rare case is dextromethorphan (41). This drug is absorbed to over 80%
in 2 h but it takes about 15–20 h to observe the maximum fraction dose absorbed. A classical IVIVC would correlate the fraction of dose absorbed versus the dose dissolved. However, in this specific case, the IVIVC would be misleading. The drug dissolves fast in the gut and is completely dissolved within 15 min. As mentioned before, > 80% will be absorbed into the enterocytes within 2 h. The drug undergoes lysosomal trapping after entering the enterocyte. As a weak base, it is highly lipophilic at physiological pH in the cytoplasm. As the drug will migrate through the enterocytes from the apical to the basolateral side, it can pass through the membranes of the lysosomes and it can enter into an aqueous environment with a slightly acidic pH. In this organel, the weak base becomes more hydrophilic and, therefore, will be entrapped in the lysosomes. That is the reason why it takes more time to appear in the blood than it takes time to be absorbed. It should be stated that for these specific drug compounds, dissolution tests are not useful surrogates for in vivo performance since the dissolution of the drug product cannot be directly correlated to the plasma levels. It is the biological system and its specific environments and drug partition between the cell compartments that determine the appearance of the drug in the central compartment and not the drug dissolution. In summary, GI drug absorption is highly impacted by different physiological factors. In vitro performance, testing should consider and include physiologically adapted test protocols to identify potential clinical relevant dosage form factors. A BCS sub-classification system, which includes acids, bases, and neutral molecules, can help to identify potential obstacles for oral drug absorption for these different groups (42). To meet all these standards, a potential in vitro apparatus, which can simulate the different GI conditions, is shown in Fig. 3.

**IN VITRO DISSOLUTION FOR A MARKETED AND GENERIC FDC DRUG PRODUCT: BIOEQUIVALENT OR NOT?—MARIVAL BERMEJO PH.D.**

Development of fixed dose drug combination (FDC) products could be challenging when both drugs do not belong to the same BCS class, i.e., when the limiting factors for their absorption are different. In the first part of the presentation, the relevance of exploring the biopharmaceutical properties of each drug in the combination product was discussed in the framework of different classification systems. The BCS system has evolved from a regulatory conservative classification framework in which the main concern is to ascertain the non-bioequivalence (non-BE) risk to a development tool which can help on the formulation strategy selection (43,44). In order to understand the biopharmaceutical limiting factors for a given drug, the cutoffs and methods for permeability and solubility estimation of BCS are modified in the developability classification system (DCS). The DCS considers a higher available fluid volume (500 mL) in the small intestine and the solubility in human intestinal fluids for solubility classification. The volume of 500 mL is calculated based on the co-administered fluid and presents residual fluid along with the GI tract (43). Another relevant addition is the differentiation between solubility-limited and dissolution-limited drugs as the formulation approaches may differ. The

![Fig. 3. Illustrative presentation of an in vitro dissolution model taking into account the different physiological barriers of the GI tract that may have a major impact on drug’s dissolution and absorption](image-url)
selection of the dissolution test to explore the risk of the non-equivalence outcome in vivo can be made based on the drug physicochemical characteristics. For that purpose, a sub-classification system from BCS was proposed by Tsume et al. (42). BCS class II drugs were sub-classified in neutral (BCS IIC), weak acids (BCS IIA), and weak bases (BCS IIB). Following these sub-divisions, the suggested dissolution tests to forecast in vivo behavior differ from class I and III for which simple dissolution apparatus (as USP II) could suffice and from class II and class IV for which a gastric compartment and an absorptive sink should be included in order to increase the in vivo predictability. To accommodate that need, several dissolution systems have been proposed in the literature and several transfer systems and two-phase or biphasic dissolution systems were described (40,45–50). In the second part of the lecture, the potential effects of formulation excipients were discussed as well as experimental preclinical models to study those effects. Excipients can affect membrane permeability and metabolism and GI motility either at the gastric emptying level or at the intestinal level. In Table I, some experimental methods with useful references are summarized.

For instance, the effect of sodium lauryl sulfate (SLS) on the intestinal permeability of fexofenadine was characterized with Doluisio’s closed loop perfusion method and further evidenced by in vivo BA studies in rats (61,62), while the relevance of gastric emptying changes due to excipients as the reason for a failed bioequivalence (BE) study was assessed with a barium sulfate gastric emptying test in rats (63). Finally, the concept of using BCS as a risk assessment tool of BE issues was with the aid of a case study of an FDC development. A valsartan/hydrochlorothiazide generic product failed twice the BE test in each one failing for one of the drugs while succeeding for the other one. The application of a biopredictive dissolution test using the gastrointestinal simulator (GIS) was successful in reproducing the in vivo outcome as differences in disintegration in the stomach chamber and differences in dissolution rate on the intestinal compartments were the apparent reasons for the in vivo failure due to different levels of sorbitol and SLS on the generic formulations. To conclude, BCS and/or DCS classification of drugs in an FDC is a tool to define the absorption-limiting factors and the relevant physiological variables affecting BA. For FDC with drugs belonging to different BCS classes, a combination in vitro dissolution methods and preclinical models is necessary to assess formulation performance.

CHALLENGES AND OPPORTUNITIES TO GRANT BCS AND DOSE STRENGTH-BASED BIOWAIVERS FOR FDC PRODUCTS—PABLO M. GONZÁLEZ PH.D.

FDC products combine two or more active pharmaceutical ingredients (API) in a finished pharmaceutical dosage form at a fixed ratio of doses (64). FDC products are approved based on the combination rule that states that each component should contribute to product effectiveness and that the combination should also be safe in a particular patient population (65,66). Safety and efficacy data can be totally (New Drug Application) or partially (505(b)(2)) original or based on previous reports (Abbreviated New Drug Application) (67). FDC products offer several advantages over co-administration of the single-entity product (SEP) such as greatest patient compliance, increased safety and efficacy, minimized abuse potential, and reduced cost for patients. They also offer opportunities for manufacturers to extend intellectual property and exclusivity along product life cycle (68). On the other hand, formulating FDC products impose several challenges related to incompatibility between APIs and incompatible interactions with certain excipients. Some drugs might degrade in presence of another (amiodaquine HCL-artesunate), others might be pharmacologically incompatible (simvastatin-telmisartan) (69), some drugs could display very different viscoelastic properties (metformin-glibenclamide), and others might interact at the absorptive (e.g., intestinal transporters) or post-absorptive (e.g., metabolic enzymes, renal transporters) level.

WHO classifies FDC products into four different scenarios regarding regulatory requirements for product registration:

- Scenario I: The new FDC product has the same APIs and doses as an existing FDC product.
- Scenario II: The new FDC product has same APIs and doses as an established regimen of single-entity products (SEP).
- Scenario III:
  - The new FDC product combines APIs with established safety and efficacy data but that have not been used in combination for that particular indication.
  - The new FDC product comprises a combination of APIs with established safety and efficacy but will be used in a different dosage regimen.

- Scenario IV: The new FDC product contains one or more new chemical entity (NCE)

BE studies are required in order to bridge pivotal clinical data of the reference listed drug (RLD) product(s) to the safety and efficacy of FDC products belonging to scenarios I and II. While the design of BE study for scenario I is standard, in scenario II, the in vivo performance (e.g., PK end-points) of the FDC product is compared to the co-administration of the SEPs. In both cases, successful BE indicates the absence of (or similar) PK interactions between APIs. However, BE studies for FDC products are challenging due to (i) potential changes in PK intra-subject variability in the combination product; (ii) non-linear PK in a line of strengths; (iii) drug-formulation interactions; and (iv) differential impact of food on API PK when administered as a combination product (70). These considerations make biowaivers a highly attractive opportunity for manufacturers to fulfill the BE requirement. Currently, WHO, the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the International Conference on Harmonization (ICH), and Health Canada allow BCS-based biowaivers for immediate release (IR) FDC products containing high-solubility APIs only (71–73). Thus, FDC products containing BCS class I and/or class III APIs could apply for a biowaiver. In general, dissolution and compositional requirements are the same as those for SEP, with some differences among jurisdictions. For BCS, class I API FDA requires the use of excipients present in currently FDA-approved IR products, while EMA encourages the use of
similar amounts of the same excipients as the reference product. The 2018 ICH Guidance on BCS-based biowaivers states that critical excipients (e.g., polysorbate 80, sorbitol) must be within ±10% of the reference product. On the other hand, there is a consensus among jurisdictions regarding the impact excipients might have on BCS class III drugs, such that agencies require excipients to be qualitatively (Q1) the same and quantitatively (Q2) very similar to the reference product. FDA and ICH guidances contain tables with allowable compositional differences of excipients (by function) relative to the reference product. The implementation of a BCS-based biowaiver for a scenario I-type FDC product is straightforward provided products are pharmaceutical equivalents, and dissolution and compositional requirements are fulfilled. Additionally, the FDA might accept BCS-based biowaivers for pharmaceutical alternatives if appropriately justified. On the other hand, a BCS-based biowaiver for scenario II-type FDC products imposes some challenges for both manufacturers and regulatory agencies. First, different single-entity RLD products might be registered in different regions, implying that a manufacturer would have to perform multiple biowaiver studies in pursuing approval in various jurisdictions. This can be further complicated by the fact that unlike FDA, EMA does not publish a list with RLD for different European countries. Second, FDC containing incompatible APIs need to incorporate a segregation technology (e.g., bilayer tables, tablet-in-tablet, etc.) in order to obtain a stable product. In this case, it might be difficult to account for the compositional requirement between the FDC product and the respective SEP. Third, dissolution methods to study FDC products with the large-dose disparity between APIs (i.e., dose ratio > 50) might be analytically challenging. This could be further complicated in cases where APIs display divergent pH-dependent stability in the physiological range. Furthermore, RLD SEPs might use different dissolution apparatus (e.g., basket or paddle) such that manufacturer might have to develop and validate two dissolution methods for one FDC product. Fourth, there is a chance for preabsorptive PK drug-drug or drug-formulation interactions (DFI) in FDC products that could be either different or absent when the SEPs are co-administered. Both FDA and EMA have published guidelines regarding studying drug-drug interactions (DDI) at the transporter level (74,75). FDA has also published methodological recommendations to study in vitro transporter-mediated DDI (74). While agencies require sponsors to study intestinal efflux transporter-mediated DDI (i.e., P-glycoprotein, breast cancer resistance protein), there is currently no published recommendation on studying potential DDI mediated by intestinal uptake transporters. This seems surprising since it is well recognized that intestinally expressed uptake transporters interact with a vast number of drugs belonging to structurally diverse chemical and therapeutic classes (76). Moreover, there is growing evidence that pharmaceutical excipients can inhibit both efflux and uptake intestinal transporters in vitro and in situ. Documented examples include PEGylated surfactants, sorbitan fatty acid esters, and polyethylene glycol (77–79). While there is a consensus that DDI or DFI might be of minor clinical relevance for BCS class I drugs, there also a concern that these interactions could greatly impact the oral absorption of low permeability APIs. FDC products also offer opportunities for developing a line of strengths that can be used to optimize therapy by dose titration. Intermediate and low strengths could apply for dose strength (DS)-based biowaiver provided there is at least one strength (typically the highest) that successfully demonstrated BE to the reference product in vivo. Dose strength-based biowaivers are applicable to APIs that are not eligible for BCS-based biowaivers and to pharmaceutical forms other than IR (i.e., modified release, delayed release). Common requirements for DS-based biowaivers among jurisdictions are linear PK in the therapeutic dose range, with a chance for bracketing approach between the highest and the lowest strength, and same manufacturing process for the strength line (80). The dose range for an FDC will be dependent on the additive or synergistic effect of the investigational drugs. The interaction between the drugs is assessed in drug-drug interaction and PK-PD studies. Subsequently, exposure-response models can be used for phase 2B dose selection (81). As in the case of BCS-based biowaivers, DS-based biowaiver requirements are an extension of those for SEPs. Tables II and III summarize FDA and EMA compositional requirements and dissolution method recommendations for DS-based biowaivers. Data presented in Tables II and III imply that manufacturers pursuing DS-based biowaivers in the US and European market might face challenges fulfilling compositional requirements for FDC products based on segregation technologies (e.g., bi-layer tablets) since EMA treats each layer as a separate entity while FDA considers bi-layer tablets as a single unit. Also, in the case of a single unit, FDC products with the large-dose disparity between APIs might be very difficult to fulfill proportionality requirements by both FDA and EMA. More specifically, EMA states that in order to calculate API/excipients proportionality, the other API must be considered an excipient. However, it is not clear whether the other API must be considered as filler for proportionality calculations. Similarly, there is no specific FDA recommendation on how to consider the other API in bi-layer tables. These discrepancies can hinder simultaneous registration of an FDC product in both the USA and Europe. Additionally, while the FDA requires BE studies for the highest dose in the strength line, EMA requires studies at the lowest strength in addition to the highest strength. Finally, the existence of different reference products among jurisdictions increases the

| Effect                        | Model                                              | Reference (PMID)     |
|-------------------------------|----------------------------------------------------|----------------------|
| Intestinal permeability       | Caco-2; in situ perfusion (rat–mouse)             | (51–55)              |
| Intestinal metabolism         | In situ perfusion in addition to mesenteric vein   | (51,56,57)           |
| Gastric emptying              | Charcoal suspension rat; phenol red + loperamide;  | (58–60)              |
| Intestinal motility           | Charcoal suspension rat                            | (58)                 |

Table I. Overview of Potential In Vitro/In Situ Methods to Apply in Order to Explore a Physiological Variable of Interest
number of studies a sponsor needs to execute if seeking approval in various regions.

CONSIDERING THE BIOPHARMACEUTICS AND PHYSICOCHEMICAL ASPECTS OF FDC—AMITAVA MITRA PH.D.

Amitava Mitra Ph.D. (Sandoz, Inc., A Novartis Division) discussed the key challenges and strategies to overcome such challenges, in achieving BE for FDC products containing two or more of active ingredients (70). The active ingredients of these products may work through different pharmacological pathways and offer advantages of additive/synergistic effect, a reduced dose of each active, and improved patient compliance. Novel FDCs of Parkinson’s drug, Levodopa, are an example of efforts to improve the clinical outcome of an old drug using new technologies and mechanisms to improve patient function (82). However, combining multiple active ingredients may complicate their individual biopharmaceutic and PK behavior. The development of controlled or modified release FDC products does add additional challenges due to changes to the drug release profiles. Such changes in the release profile can change the biopharmaceutic and pharmacokinetic profiles of the API. Interested readers should review the following published references [70,83–85]. The importance of critically reviewing the physicochemical and biopharmaceutical properties and their impact on PK of the individual drugs being considered for the FDC was also discussed. Gaining a thorough understanding of the PK properties of the individual drugs along with the formulation variables being considered for the FDC is an equally important consideration. Pilot BA studies designed to answer the most pertinent questions relating to the FDC strategy are important and encouraged. However, underpowered studies with too many variables can further complicate an already complex issue and should be avoided. Pivotal BE studies should be designed with due consideration of all the physicochemical, biopharmaceutic, and PK data for the compound from all sources. BE study designs specific to highly variable drugs such as scaled BE or crossover replicate designs may be considered. Leveraging the knowledge gained from varying but synergistic techniques such as in vitro solubility/dissolution studies, in silico absorption models and IVIVC’s, in vivo preclinical animal models, and the available in vivo clinical data is paramount to the success of the FDC strategy for

### Table II. Comparative compositional requirements to grant dose strength-based biowaivers by FDA and EMA

| Criteria                  | FDA                                                                 | EMA                                                                 |
|---------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| General composition       | All ingredients and APIs are in the same proportion between diff. strengths | Q1 the same and Q2 proportional across different strengths          |
| High-potency APIs         | • Total weight nearly constant across strengths (± 10% from bio-batch) | • Amount of API < 5% core weight or capsule filling                  |
|                           | • Q1the same across strengths                                        | • Amount of excs. Constant only API varies                           |
|                           | • Only APIs vary across strengths, and one or more excps.             | • Only filler changes to account for changes in APIs                 |
| ANDA                     | Proportion between API and excps. might vary across strengths if same BA is achieved | No special considerations                                             |
| Bi-layer tablets          | Bimodal tablets are considered as a single unit                       | Each layer is considered independently                               |
| Prolonged Release         | • Beaded capsules: only number of beads varies across strengths       | • Multiple unit formulation: BEq for the highest strength            |
|                           | • Single-unit products similar general requirements                    | • Single-unit formulation: bracketing approach                       |
| FDC                      | Not discussed                                                        | • Release controlling (or coating) excps. must be the same for the line of strengths. |

Adapted from (80)

### Table III. Dissolution method recommendations by FDA and EMA for dose strength-based biowaivers

| Criteria | FDA                                                                 | EMA                                                                 |
|----------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| IR products | (i) Compendial method                                                | (i) pH (1.2, 4.5, 6.8) and QC method                                 |
|          | (ii) FDA recommended/USP general chapter                             | (ii) If sink condition cannot be achieved at a particular pH for all strengths, compare to dissolution profile of RLD at same dose or using multiple units of lower strengths |
|          | (iii) Develop new method using diff. agitation speeds, pH (1.2, 4.5, 6.8). Water can be used. Add surfactants if API is poorly soluble |                                                                 |
| MR products | • If no compendial method submit (ii) + pH (1.2, 4.5, 6.8) for comparisons |                                                                 |
|          | • Select the most discriminating conditions (agitation, media) based on in vitro and in vivo data |                                                                 |

Adapted from reference [80]
a given combination. Two case studies were discussed where the use of oral absorption modeling, dissolution data, and clinical PK data was used to successfully develop FDC products. In the first case study, the development of a triple combination product was discussed, where one of the active ingredients had a highly variable Cmax and the other active ingredient had a long Tmax due to bile secretion and slow absorption. In this case, oral absorption modeling was key to understanding the impact of formulation changes on PK of the three actives and ultimately in the development of the FDC product. In the second case study, the development of a double combination product was discussed, where one of the active ingredients was a weak base with high intra-subject CV and steep pH-solubility profile. In this case, data from several relative BA studies and a thorough understanding of the PK and biopharmaceutic properties helped with the successful development of the FDC.

CURRENT REGULATORY REQUIREMENTS TO ASSESS BIOEQUIVALENCE OF FDC PRODUCTS WORLDWIDE (EU/USA/LATIN AMERICA/JAPAN)—ALEXIS ACEITUNO PH.D.

Although one of the purposes is to combine drugs at fixed dose ratios to simplify the treatment of chronic diseases and improve patient adherence, there is a general consensus that this rationale cannot be the only goal behind any development or formulation design (86). An overview regarding regulations for filing FDC products throughout various jurisdictions around the world shows that progress on this matter has been rather slow. Overall, the development of FDC products by combining previously approved mono-products or starting from the co-formulation of NCEs can follow limited regulatory pathways. Under US regulations, the FDCs regulatory fundamentals are described in the Code of Federal Regulations and guidelines that outline the requirements for FDC product approval. The introduction of co-development guidance in 2013 reflects the importance of these pharmaceutical products from a regulatory perspective (65). The guidances describe that drug product efficacy can rely on BE testing if there is no change in dosing or proposed therapeutic indication for a novel FDC or clinical data are required otherwise. FDC products could follow one of the following regulatory pathways: 505 b(1), 505 b(2), or 505 j covering all the possibilities from new development to generic development. On the other hand, EMA launched several guidelines with respect to the clinical development of FDC products reflecting the proposed therapeutic used and indications of any FDC development (66). The guidance describes three possible situations with specific requirements for demonstrations of efficacy: (1) the use of an FDC product as add-on treatment if there is a deficient response to one or more drugs to be included in the proposed combination. Drug-drug (DDI) or PK interaction study may be required if the combination poses a threat with potential clinical consequences and (2) substitution by an FDC product when a reduction of pill burden is sought after. BE testing is required and special attention should be paid if the FDC product is dosed at different time intervals, and (3) FDC therapy initiation if the FDC product has not been used previously for any particular indication. Both clinical and pk trial, as well as DDI study, should be performed and submitted prior to approval. In Latin America, there is only one specific guidance for registration of FDC products since 2010 (87). It describes the definition of FDC products, general consideration for filing, and regulatory requirements that depend on the proposed dose scheme or the drugs to be combined. FDC approval can be granted under the following conditions: (1) An FDC product contains the same actives, dose, and dose regimes as mono-products used concomitantly; therefore, the safety and efficacy profiles are well known; to demonstrate efficacy, a BE study may be sufficient; (2) the same conditions as in “(1),” but FDC product is going to be used in novel dose or new therapeutic indication and therefore a phase III clinical trial is required; (3) the combination contains one or more new active ingredients and phase I, II, and III clinical trials are required to gain approval. In general, there is not a globally applicable guideline for FDC product registration, but for specific therapeutic classes and four general cases that are described in a WHO technical report, aiming at guiding pharmaceutical companies for development, approval, and marketing FDC products under less developed jurisdictions (64). Although generic and hybrid submission pathways seem to be sufficient under most jurisdictions, preclinical and clinical data for novel combinations will always be needed if individual components in FDC products are either known or they are new investigational drugs. However, the idea still persists among regulated entities that different jurisdictions around the world should give more importance to convenience/compliance as a rationale for developing FDC products either containing authorized/new drug entities or authorized drugs only bearing in mind patient’s satisfaction or reduced/contained health costs (88). If generic development is allowed, a BE study design for a FDC product should consider the same principles as if the drugs were given alone, looking for the achievement of equivalence in PK profiles for each FDC active ingredient and their respective either reference FDC or reference mono-products. At this point, it is important to realize that PK interactions may have more critical consequences with FDC products than the same drugs given as mono-products concomitantly. To conclude, when comparing jurisdictions to obtain FDC product approval, it seems necessary that a balance should be reached between an overcautious registration approach and the potential large public health benefits that would arise from affordable FDC products of proved efficacy. The achievement of broad harmonization in the understanding and application of existent technical guidelines and requirements for FDC product development and registration is still a pending matter.

FORMULATION DESIGN, CHALLENGES, AND DEVELOPMENT CONSIDERATIONS FOR FIXED DOSE COMBINATION (FDC) OF ORAL SOLID DOSAGE FORMS—DIVYAKANT DESAI PH.D.

For formulation scientists without prior experience of the FDC development, two decision trees were discussed to select the most suitable formulation development strategy. The first decision tree was related to the formulation design for an FDC product (Fig. 4).

If two drugs are chemically incompatible, multi-layer tablet or a drug-specific multi-particulate system was
proposed. If they are compatible, then a monolithic system was proposed unless there is a need to keep them apart in order to maintain the dissolution profiles comparable to the respective single-entity product. The second decision tree was about the selection of the manufacturing process for an FDC product (Fig. 5).

Fig. 4. Decision tree for the formulation design of a FDC. Figure adapted from Desai and colleagues (89). Copyright Taylor and Francis 2013

Fig. 5. Decision tree for the manufacturing process selection of a FDC. Figure adopted from Desai and colleagues (89). Copyright Taylor and Francis 2013
The drug loading in the formulation dictated the selection of the manufacturing process. If the drug loading is high, a hot melt extrusion (HME) or a bi-layer method of manufacturing was proposed. For a formulation with a low drug loading, an active coating approach was proposed. One of the crucial factors in the manufacturing process selection is a pharmaceutical scientist prior to experience with the manufacturing process under consideration. A monolithic formulation system, where two drugs are incorporated in a single-dose unit, is considered the most simple formulation approach. However, a case study was presented where a second drug, hydrochlorothiazide (HCTZ), was added to the existing formulation of a hypertensive drug (90). It was shown that povidone (a binder) and poloxamer (a wetting agent) triggered HCTZ degradation under accelerated storage conditions by solubilizing HCTZ in available moisture. Replacement of povidone by Starch 1500, resolved the stability issue and removal of poloxamer, did not impact the BE study adversely. For a bi-layer tablet formulation approach, which is normally used to keep two incompatible drugs apart or to maintain two drug release profiles, few critical formulation factors were presented. Those factors include the selection of excipient with high fragmentation tendency such as the lactose in the first layer, more deformable material such as microcrystalline cellulose in the second layer, and the weight ratio of not more than 1:6 for two layers. It was also emphasized that the tamping force for the first layer should be able to reduce the volume without sacrificing the surface roughness which is essential for the adhesion of the second layer. Two case studies were presented with respect to the bi-layer formulation approach. In the first case study, the compressibility of an extended release metformin formulation was improved by the addition of 1% w/w silicon dioxide. In the second case study, two different grades of fumed silica behaved differently in a bi-layer tablet formulation (91). Aeroperl 200 did not cause layer separation but Aeroperl 300 did. Aeroperl can adsorb relatively large amounts of moisture at any humidity level due to its greater surface area, but it does not retain moisture when the humidity decreases. In contrast, Aerosil adsorbs relatively smaller amounts of moisture but it retains moisture due to its large pore sizes. It was hypothesized that the moisture not retained by Aeroperl could be available for interactions with other layer excipients such as crospovidone. The third formulation technique presented was an active coating technology. An active coating can also be used to maintain two separate release profiles and to separate two incompatible drugs. A case study was presented to show how acid and base sensitive molecule was stabilized selecting and minimizing the excipients in a coating material API come in intimate contact with. For example, the 1-mg drug is placed with 99 mg of excipients for a 100-mg tablet; the 1-mg drug can react with 99 mg of excipients. However, if the 1-mg drug is placed with 9 mg of coating material, the amount of available for a reaction is reduced drastically. It is also a useful technology to make a tablet for a compression sensitive molecule. Although the active coating is useful, it is not as widely used as other technologies because it presents two big challenges. The first challenge is how to detect coating endpoint so that tablets with correct potencies can be manufactured. If a coating process is stopped early, tablets may be sub-potent. On the other hand, if the coating is stopped late, tablets may be super potent. The second challenge is content uniformity (active coat uniformity). The content uniformity can be influenced by various process parameters such as pan load, coating time, number of coating guns, and spray quality. A mathematical model was presented in which model parameters were linked with the process parameters for scale-up. It was shown that the model correctly predicted coating uniformity of tablet weighing 200 to 1450 mg in different shapes at a 450-kg commercial scale. In summary, the decision trees are very useful to explore the most suitable formulation and manufacturing process for an FDC formulation. Each formulation approach for an FDC will have its own unique challenges but as illustrated by various case studies, it is possible to overcome these challenges to develop a rugged formulation and a commercially viable manufacturing process using various process analytical technologies (PAT).

CLINICAL PHARMACOLOGY ASPECTS OF FIXED DOSE COMBINATION DRUG DEVELOPMENT—DAKSHINA MURTHY CHILUKURI PH.D.

Combination products are defined in the Code of Federal Regulations [21 CFR 3.2 (e)] as categories of drug-drug combination products. These products could be two or more approved drugs or investigational drug(s) developed along with an approved drug(s) or two or more investigational drugs developed together. The final products can be FDCs, co-packaged products or separate individual products administered together. Among the reasons why these products are developed are the additive/synergistic effects of drugs for the same disease (e.g., anti-viral and cough/cold drug products). Sometimes, when two drugs have complementary mechanisms of action, they are developed for the same disease as an FDC product. For instance, combining a beta-lactam with a beta-lactamase inhibitor allows for selective killing of bacteria that would otherwise be resistant to the beta-lactam. There are examples of FDCs where one component is included to reduce the adverse events of the other component (e.g., naproxen/esomeprazole delayed release tablets). Most FDCs are oral but there are examples of inhalational (e.g., tiotropium/olodaterol for chronic obstructive pulmonary disease (COPD)) and ophthalmic products (e.g., netarsudil/latanoprost for lowering intraocular pressure). The purpose of this presentation was to provide an overview of the clinical pharmacology considerations in FDC development. FDC development offers interesting challenges to drug developers. If two or more new molecular entities (NMEs) are being developed as an FDC then dosing finding studies of the drugs are generally required to determine the appropriate dose of each drug to be combined. If the FDC product contains drug component(s) not included in approved combination therapy, then a factorial design clinical efficacy/safety study may be required to demonstrate the contribution of each drug component. Drug administration challenges such as the effect of food on the FDC will generally need to be addressed. This scenario could get more
complicated when the various drugs proposed in the FDCs have different requirements for administration under fed and fasted conditions or when the drugs have different dosing frequency. These scenarios generally require a closer look at the FDC formulation and potential for additional BA frequency. These scenarios generally require a closer look at fed versus fasted conditions or when the drugs have different dosing requirements for administration under fed and fasted conditions. When they do so, the underlying problems can be unraveled which will be taken into account by the FDA guidance entitled “Codevelopment of Two or More New Investigational Drugs for Use in Combination” lays out the scenarios where a factorial design study may be appropriate to establish the contribution of the individual components in the FDC.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

Market access for FDC products is challenging in terms of achieving BE to co-administration of the individual monoproducts, but also because of formulation challenges (compatibility of APIs, doses). However, we should not neglect the impact of GI physiology on oral drug behavior which can result in intersubject differences in systemic outcome, potentially leading to failures in BE studies. Therefore, it is important to finalize a clear link between formulation strategy and clinical evaluation, supported by guidelines of regulatory authorities. In addition, the contribution of in vitro predictive dissolution testing can help assist regulatory decisions with respect to the approval of FDC products in a sense that these models identify the underlying GI variables playing a crucial role in the absorption process inside the GI tract. From an academic point of view, these clinically relevant dissolution models can be optimized and validated when pharmaceutical companies would share their non-BE formulations (i.e., clinical failures). When they do so, the underlying problems can be unraveled which will be taken into account by formulations scientists when formulating FDC products.

FUNDING INFORMATION

The authors received financial support from the Flemish Research Council (FWO – applicant number: 12R2119N).

COMPLIANCE WITH ETHICAL STANDARDS

Disclaimer This report represents the scientific views of the authors and not necessarily that of the regulatory authorities presented in this manuscript (U.S. Food and Drug Administration and ANAMED).

REFERENCES

1. Janssen P, Vanden Berghe P, Verschueren S, Lehmann A, Depoortere I, Tack J. Review article: the role of gastric motility in the control of food intake. Aliment Pharmacol Ther. 2011;33:880–94.
2. Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9:271–85.
3. Vantrappen G, Janssens J, Hellemans J, Ghoo Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59:1158–66.
4. Vantrappen GR, Peeters TL, Janssens J. The secretory component of the interdigestive migrating motor complex in man. Scand J Gastroenterol. 1979;14:663–7.
5. Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019;26:3–10.
6. Camilleri M, Malagelada JR, Brown ML, Becker G, Zinsmeister AR. Relation between antral motility and gastric emptying of solids and liquids in humans. American journal of physiology Renal physiology, American journal of physiology Renal physiology [Internet]. 1985 [cited 2017 May 22]. Available from: https://mayoclinic.pure.elsevier.com/en/publications/relation-between-antral-motility-and-gastric-emptying-of-solids-a.
7. Farré R, Tack J. Food and symptom generation in functional gastroduodenal disorders: physiological aspects. Am J Gastroenterol. 2013;108:698–706.
8. Pasricha PJ, Camilleri M, Hasler WL, Parkman HP. White Paper AGA: Gastroparesis: clinical and regulatory insights for clinical trials. Clin Gastroenterol Hepatol. 2017;15:1184–90.
9. Hens B, Tsume Y, Bermejo M, Paixao P, Koenigsknecht MJ, Baker JR, et al. Low buffer capacity and alternating motility along the human gastrointestinal tract: implications for in vivo dissolution and absorption of ionizable drugs. Mol Pharm. 2017;14:4281–94.
10. Paixão P, Bermejo M, Hens B, Tsume Y, Dickens J, Shedden K, et al. Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: a multi-compartment stomach approach. Eur J Pharm Biopharm. 2018;129:162–74.
11. Oberle RL, Chen TS, Lloyd C, Barnett JL, Owyang C, Meyer J, et al. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology. 1999;99:1275–82.
12. Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, Amidon GL, et al. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11:3039–47.
13. Parker HL, Tucker E, Blockshaw E, Hoad CL, Marciani L, Perkins A, et al. Clinical assessment of gastric emptying and sensory function utilizing gamma scintigraphy: establishment of reference intervals for the liquid and solid components of the Nottingham test meal in healthy subjects. Neurogastroenterol Motil. 2017;29.
14. Parker H, Hoad CL, Tucker E, Costigan C, Marciani L, Gowland P, et al. Gastric motor and sensory function in health assessed by magnetic resonance imaging: establishment of
reference intervals for the Nottingham test meal in healthy subjects. Neurogastroenterol Motil. 2018;30:e13463.
15. Cassilly D, Kantor S, Knight LC, Maurer AH, Fisher RS, Semler J, et al. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule. antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil. 2008;20:311–9.
16. Diaz Tartera HO, Webb D-L, Al-Saffar AK, Halim MA, Lindberg G, Sangfelt P, et al. Validation of SmartPill® wireless motility capsule for gastrointestinal transit time: intra-subject variability, software accuracy and comparison with video capsule endoscopy. Neurogastroenterol Motil. 2017;29:1–9.
17. Heissam K, Abrecht N, Hoad CL, Wright J, Menys A, Murray K, et al. Measuring fasted state gastric motility before and after a standard BA/BE 8 oz drink of water: validation of new MRI imaging protocols against concomitant perfused manometry in healthy participants. Annual AAPS Meeting. Washington, DC, November 4–7 2018.
18. Hoad C, Clarke C, Marciani L, Graves MJ, Corsetti M. Will MRI of gastrointestinal function parallel the clinical success of cine cardiac MRI? BJR. 2018;92:20180433.
19. Schiller C, Fröhlich C-P, Giessmann T, Siegmund W, Mönnikes H, Hosten N, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22:971–9.
20. Hens B, Bolger MB. Application of a dynamic fluid and pH model to simulate intraluminal and systemic concentrations of a weak base in GastroPlus™. J Pharm Sci. 2019;108:305–15.
21. Riethorst D, Mols R, Duchateau G, Tack J, Brouwers J, Annaert P, et al. Ambulatory assessment of colonic motility as studied in humans and animals using the electromagnetic capsule tracking system. J Pharm Sci. 2019;108:268–78.
22. Riethorst D, Mols R, Duchateau G, Tack J, Brouwers J, Annaert P, et al. In vivo predictive dissolution (IPD) methodology and IVIVC. J Pharm Sci. 2018;107:1458–65.
23. Dahlgren D, Roos C, Lundqvist A, Abrahamsson B, Tannergren M, et al. Regional intestinal permeability of three model drugs in human. Mol Pharm. 2016;13:5031–21.
24. Lennernd H. Human intestinal permeability. J Pharm Sci. 1998;87:403–10.
25. Dahlgren D, Roos C, Sjögren E, Lennernd H. Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods. J Pharm Sci. 2015;104:2702–26.
26. Vuylst B, Riethorst D, Brouwers J, Tack J, Annaert P, Augustijns P. Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. Int J Pharm. 2015;487:736–44.
27. Corsetti M, Costa M, Bassotti G, Bharucha AE, Borrelli O, DINNING PG. First “translational” consensus on terminology and definition of colonic motility as studied in humans and animals by means of manometric and non-manometric techniques. Nat Rev. in press.
28. Mark EB, Poulsen JL, Haase A-M, Eversen M, Gregersen T, Schlageter V, et al. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system. Neurogastroenterology & Motility. 2019;31:e13451.
29. Wilkinson-Smith VC, Major G, Ashleigh L, Murray K, Hoad CL, Marciani L, et al. Insights into the different effects of Food on intestinal secretion using magnetic resonance imaging. J Parenter Enteral Nutr. 2018;42:1342–8.
30. Costa M, Winklendt L, Keyhtiny L, Brookes SJH, Dinning PG, Spencer NJ. New insights into neurogenic cyclic motor activity in the isolated guinea-pig colon. Neurogastroenterol Motil. 2017;29:1–13.
31. Amidon GL, Lennernd H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.
32. Wei H, Dalton C, Di Maso M, Kanfer I, Löbenberg R. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur J Pharm Biopharm. 2008;69:1046–56.
54. Bermejo MV, Pérez-Varona AT, Segura-Bono MJ, Martín-Villo dre A, Plà-Delínna JM, Garrisones TM. Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption I. Studies with polysorbate and taurocholate in rat colon. Int J Pharm. 1991;99:221–31.

55. Carmona-Báez G, del Bermejo-Acón MV, Rius-Alaréco F, Martín-Villo dre A. Experimental studies on the influence of surfactants on intestinal absorption of drugs cefadroxil as model drug and sodium taurocholate as natural model surfactant: studies in rat colon and in rat duodenum. Arzneimittelforschung. 1999;49:44–50.

56. Brouwers J, Mols R, Annaert P, Augustijns P. Validation of a differential in situ perfusion method with mesenteric blood sampling for intestinal drug interaction profiling. Biopharm Drug Dispos. 2013;31:278–85.

57. Mols R, Brouwers J, Schinkel AH, Annaert P, Augustijns P. Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling. Drug Metab Dispos. 2009;37:1334–7.

58. Guillaume P, Provost D, Lacroix P. Gastrointestinal models: intestinal transit, gastric emptying, and ulcerogetic activity in the rat. Curr Protoc Pharmacol. 2008;Chapter 5:Unit5.3.

59. Goinen U, Guillaume P, Castagné V. Comparison of the effects of clonidine, loperamide and metoclopramide in two models of gastric emptying in the rat. Fundam Clin Pharmacol. 2015;29:98–94.

60. Pestel S, Martin H-J, Mai er G-M, Guth B. Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. J Pharmacol Toxicol Methods. 2006;54:200–14.

61. Gundogdu E, Mangas-Sanjuan V, González-Alvarez I, Bermejo M, Karasulu E. In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate. Eur J Drug Metab Pharmacokinet. 2012;37:65–75.

62. Gundogdu E, Alvarez IG, Karasulu E. Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies. Int J Nanomedicine. 2011;6:1631–40.

63. Colon-Useche S, González-Alvarez I, Mangas-Sanjuan V, González-Alvarez M, Pastoriza P, Molina-Martínez I, et al. Investigating the discriminatory power of BCS-biowaiver in vitro methodology to detect bioavailability differences between immediate release products containing a class I drug. Mol Pharm. 2015;12:3167–74.

64. World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organ Tech Rep Ser. 2005;929:1–142 backcover.

65. US Food & Drug Administration. Guidance for industry on fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV; availability [Internet]. Federal Register. 2006 [cited 2019 Jan 15]. Available from: https://www.federalregister.gov/documents/2006/10/18/E6-17324/guidance-for-industry-on-fixed-dose-combinations-co-packaged-drug-products-and-single-entity.

66. European Medicines Agency. Guideline on clinical development of fixed combination medicinal products. 2017;12. Last accessed on March 6, 2019.

67. When to Submit an ANDA vs. a 505(b)(2) Application: FDA Discusses in Draft Guidance [Internet]. [cited 2019 Jan 15]. Available from: https://www.raps.org/regulatory-focus™-news-articles/2017/10/when-to-submit-an-anda-vs-a-505(b)(2)-application-fda-discusses-in-draft-guidance.

68. Podolsky SH, Greene JA. Combination drugs. Drugs. 2006;35:488–91.

69. Kohlrausch A. Bilayer tablet of telmisartan and simvastatin [Internet]. 2006 [cited 2019 Jan 15]. Available from: https://patents.google.com/patent/US20060078615A1/en.

70. Mitra A, Wu Y. Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J. 2012;14:464–55.

71. Food & Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system guidance for industry [Internet]. 2015 [cited 2017 Jan 17]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceRegulatoryInformation/GuidanceDocuments/ucm070246.pdf.

72. European Medicines Agency. Guideline on the investigation of bioequivalence [Internet]. 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.

73. Canada H, Canada H. Guidance document: biopharmaceutics classification system based biowaiver [Internet]. [cited 2019 Jan 15]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/applications-submissions/guidance-documents/biopharmaceutics-classification-system-based-biowaiver.html.

74. US Food & Drug Administration. In vitro metabolism- and transporter-mediated drug-drug interaction studies, and clinical drug interaction studies-study design, data analysis, and clinical implications; draft guidances for industry; availability [Internet]. Federal Register. 2017 [cited 2019 Jan 15]. Available from: https://www.federalregister.gov/documents/2017/10/25/2017-23012/in-vitro-metabolism%2D%2Dand-transporter-mediated-drug-drug-interaction-studies-and-clinical-drug.

75. European Medicines Agency. European Medicines Agency updates guideline on drug interactions [Internet]. 2012 [cited 2019 Jan 15]. Available from: https://www.ema.europa.eu/en/news/european-medicines-agency-updates-guideline-drug-interactions.

76. Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov. 2008;7:205–20.

77. Dahlgren D, Roos C, Lundqvist A, Tannergren C, Langpith P, Sjöblom M, et al. Preclinical effect of absorption modifying excipients on rat intestinal transport of model compounds and the mucosal barrier marker 51Cr-EDTA. Mol Pharm. 2017;14:2423–51.

78. Engel A, Oswald S, Siegmund W, Keiser M. Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm. 2012;9:2577–81.

79. Otter M, Oswald S, Siegmund W, Keiser M. Effects of frequently used pharmaceutical excipients on the organic cation transporters 1-3 and peptide transporters 1/2 stably expressed in MDCKII cells. Eur J Pharm Biopharm. 2017;112:187–95.

80. Cardot J-M, Garcia-Arieta A, Paixao P, Tasevska I, Davit B. Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US-FDA submission. Eur J Pharm Sci. 2018;111:399–408.

81. Maltais F, Hamilton A, Voß F, Maleki-Yazdi MR. Dose determination for a fixed-dose drug combination: a phase II randomized controlled trial for tiotromip/olodaterol versus tiotropium in patients with COPD. Adv Ther. 2019;36:962–8.

82. Silver DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Staleve). Expert Rev Neurother. 2004;4:889–99.

83. Dey S, Chattopadhyay S, Mazumder B. Formulation and Evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release. Biomed Res Int [Internet]. 2014 [cited 2019 Apr 25]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909790/.

84. Riekens MS, Engelen A, Appeltans B, Rombaut P, Stulzer HK, Van den Mooter G. New perspectives for fixed dose combinations of poorly water-soluble compounds: a case study with ezetimibe and lovastatin. Pharm Res. 2016;33:1259–75.

85. Oh J-H, Lee JE, Kim YJ, Oh T-O, Han S, Jeon EK, et al. Designing of the fixed-dose gastroretentive bilayer tablet for sustained release of metformin and immediate release of atorvastatin. Drug Dev Ind Pharm. 2016;42:340–9.

86. Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registrability of the polypill. Eur Heart J. 2006;27:1651–6.

87. Guia para Registro de Novas Associações em Dose Fixa - Busca - Anvisa [Internet]. [cited 2019 Jan 15]. Available from: http://portal.anvisa.gov.br/resultado-de-busca?p_p_id=101&pp_col_id=column-1&p_p_col_count=1&_101_struts_action=%2Fasset_publisher%2Fview_content%2F101_assetEntryId=352621&_101_type=DOCUMENT.

88. Gautam Y, Bjerrum OJ, Schmigelow M. The wider use of fixed-dose combinations emphasizes the need for a global
approach to regulatory guideline development. Drug Inf J. 2015;49:197–204.
89. Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18:1265–76.
90. Desai D, Rinaldi F, Kothari S, Paruchuri S, Li D, Lai M, et al. Effect of hydroxypropyl cellulose (HPC) on dissolution rate of hydrochlorothiazide tablets. Int J Pharm. 2006;308:40–5.
91. Narang AS, Rao VM, Desai DS. Effect of antioxidants and silicates on peroxides in povidone. J Pharm Sci. 2012;101:127–39.
92. US Food & Drug Administration. Guidance, compliance, & regulatory information [Internet]. [cited 2019 Mar 5]. Available from: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/default.htm.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.